Align Technology, Inc. vs VanEck Australian Floating Rate ETF — how do they compare? Align Technology, Inc. trades at $171.94 (market cap $12.29B), while VanEck Australian Floating Rate ETF trades at $50.93. Which is the better fit depends on your goals.
| ALGN | FLOT | |
|---|---|---|
Market Cap | $12.29B | — |
Sector | Health | Sector/Thematic |
52-Week High | $197.51 | $51.09 |
52-Week Low | $124.88 | $50.72 |
Enterprise Value | $11.30B | — |
Signals from Pluang's Aura AI — not financial advice
ALGN trades at $176.04, up 1.37% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported record Q2 2026 revenue of $1.06 billion, driven by strong clear aligner volume growth. Analyst sentiment is positive, with 73% recommending buy, and institutional activity shows mixed positioning amid strategic initiatives like board changes and patent wins in China.
The outlook remains favorable due to solid fundamentals and international expansion, but risks include competitive pressures in digital dentistry and reliance on North American market stability. Earnings growth and margin improvements are key catalysts, though valuation multiples near five-year lows suggest potential upside if execution continues.
FLOT trades at $50.925 with minimal daily movement (+0.01%). Technical indicators show a bearish trend with all 13 moving averages signaling sell. The ETF maintains consistent dividend payments with recent distributions of $0.17-$0.18. Market focus remains on Federal Reserve policy as floating rate bonds like FLOT could benefit from potential rate hikes later in 2026.
FLOT offers exposure to high-quality floating rate bonds with a 4.0% SEC yield, positioned as a cash alternative with slightly higher returns than T-bills. The primary catalyst is potential Fed rate hikes, though the bearish technical picture and inflation uncertainty present near-term headwinds for price appreciation.
Trailing returns across standard periods
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →